Drug-induced lupus: An update on its dermatologic aspects

Lupus

Volumn 18, Issue 11, 2009, Pages 935-940

  Marzano, Angelo V ^a   Vezzoli, Pamela ^a   Crosti, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Discoid lupus erythematosus; Subacute lupus erythematosus; Systemic lupus erythematosus

Indexed keywords

ACEBUTOLOL; AMFEBUTAMONE; ANTINUCLEAR ANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTONE ANTIBODY; HYDRALAZINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; ISONIAZID; LANSOPRAZOLE; LEFLUNOMIDE; METHYLDOPA; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PROCAINAMIDE; QUINIDINE; RO ANTIBODY; TAMOXIFEN; TEGAFUR; TERBINAFINE; THIAZIDE DIURETIC AGENT; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UFT; UNINDEXED DRUG;

ALOPECIA; ANNULAR ERYTHEMA; BULLOUS SKIN DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISCOID LUPUS ERYTHEMATOSUS; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; ERYTHEMATOSQUAMOUS SKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; LUPUS LIKE SYNDROME; MOUTH ULCER; NECROTIZING ARTERITIS; NONHUMAN; PATHOGENESIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SKIN DEFECT; SKIN EDEMA; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS RASH; URTICARIA;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; ANTITUBERCULAR AGENTS; AUTOANTIBODIES; HUMANS; HYDRALAZINE; ISONIAZID; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MINOCYCLINE; PHARMACEUTICAL PREPARATIONS; PROCAINAMIDE; SKIN DISEASES;

EID: 70349498498     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106176     Document Type: Review

References (58)

1. Hess E. Drug-related lupus. N Engl J Med 1988; 318: 1460-1462.
2. Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Derm Syphilol 1945; 51: 190-192.
3. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103: 49-51.
4. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: A cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-1415.
5. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157-166.
6. Dalle Vedove C, Del Giglio M, Schena D, Girolomoni G. Druginduced lupus erythematosus. Arch Dermatol Res 2009; 301: 99-105.
7. Uetrecht J. Current trends in drug-induced autoimmunity. Toxicology 2005; 4: 309-314.
8. Yoshimasu T, Hiroi A, Uede K, Furukawa F. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 2001; 11: 54-57.
9. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alfa agents. Semin Arthritis Rheum 2008; 37: 381-387.
10. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Druginduced lupus erythematosus. Autoimmunity 2005; 38: 507-518.
11. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925-931.
12. Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol 2005; 46: 266-269.
13. Fenniche S, Dhaoui A, Ammar FB, Benmously R, Marrak H, Mokhtar I. Acebutolol-induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol 2005; 18: 230-233.
14. Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol 2008; 88: 87-89.
15. Marzano AV, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 2008; 17: 329-331.
16. DeBandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 2005; 7: R545-R551.
17. Bentley DD, Graves JE, Smith DI, Hefferman MP. Efalizumabinduced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006; 54: S242-S243.
18. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol 2007; 56: S114-S116.
19. Schneider SW, Staender S, Schluter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006; 142: 115-116.
20. Rubin RL. Drug-induced lupus. Toxicology 2005; 209: 135-147.
21. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: How do they arise. Immunol Today 1998; 19: 133-141.
22. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207-216.
23. Hess DA, Sisson ME, Suria MJ, et al. Cytotoxicity of sulfomanide reactive metabolites: Apoptosis and selective toxicity of CD8+ cells by the hydroxylamine of sulfamethoxazole. FASEB J 1999; 13: 1688-1698.
24. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance: A murine model of drug-induced lupus. J Clin Invest 1997; 99: 1888-1896.
25. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causing autoimmunity. Nat Med 2000; 6: 298-305.
26. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC.Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995; 154: 3025-3035.
27. Yung R, Chang S, Hemati N, Johnson KJ, Richardson BC. Mechanism of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997; 40: 1436-1443.
28. Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T-cells overexpressing lymphocyte function-associated antigen become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97: 2866-2871.
29. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNFa therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006; 26: 209-214.
30. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001; 144: 958-966.
31. Marzano AV, Frezzolini A. Caproni, et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007; 20: 557-566.
32. Vasoo S. Drug-induced lupus: An update. Lupus 2006; 15: 757-761.
33. Kauffman CL, Sabbagh AK. Lupus erythematosus, Drug-induced. eMedicine J 2001; 2. http//www.emedicine.com/derm/topic107.htm
34. Watts RA. Muscoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000; 12: 49-52.
35. Mohan AK, Edwards ET, Coté TR, Siegel JN, Braun MM. Druginduced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002; 360: 646.
36. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002; 137: 625-626.
37. Maini R, Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Attract Study Group. Lancet 1999; 354: 1932-1939.
38. Schaffer JV, Davidson DM, McNiff JM, Bolognia JL. Perinuclear antineutrophilic cytoplasmatic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001; 44: 198-206.
39. Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients withminocycline-induced autoimmune phenomena. Am J Med 1998; 105: 484-487.
40. Elkayam O, Yaron M, Caspi D.Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996; 55: 769-771.
41. Elkayam O, Yaron M, Caspi D.Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996; 55: 769-771.
42. Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S. Minocycline-related lupus. Lancet 1992; 340: 1553.
43. Grossman L, Barland P. Histone reactivity of drug-induced antinuclear antibodies. A comparison of symptomatic and asymptomatic patients. Arthritis Rheum 1981; 24: 927-931.
44. Sontheimer RD. Subacute cutaneous lupus erythematosus: A quarter century's perspective. In: Sarzi-Puttini P, Doria A, Girolomi G, Kuhn A, (eds), The skin in systemic autoimmune diseases. Amsterdam: Elsevier, 2006. pp. 65-86.
45. Marzano AV, Facchetti M, Alessi E. Poikilodermatous subacute cutaneous lupus erythematosus. Dermatology 2003; 207: 285-290.
46. Marzano AV, Berti E, Gasparini G, Caputo R. Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions. Br J Dermatol 1999; 141: 720-724.
47. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol 1994; 130: 1262-1268.
48. Sontheimer RD, Stastny P, Gilliam JN. Human histocompatibility antigen associations in subacute cutaneous lupus erythematosus. J Clin Invest 1981; 67: 312-316.
49. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982; 97: 664-671.
50. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSApositive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
51. Amerio P, Innocente C, Feliciani C, Angelucci D, Gambi D, Tulli A. Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine. Eur J Dermatol 2006; 16: 281-283.
52. Marzano AV, Borghi A, Mercogliano M, Facchetti M, Caputo R. Nitrendipine-induced subacute cutaneous lupus erythematosus. Eur J Dermatol 2003; 13: 213-216.
53. Aydogan K, Karadogan SK, Balaban A, Tunali S. Lupus erythematosus associated with erythema multiforme: Report of two cases and review of the literature. J Eur Acad Dermatol Venereol 2005; 19: 621-627.
54. Rowell NR, Beck JS, Anderson JR. Lupus erythematosus and erythema multiforme-like lesions. A syndrome with characteristic immunological abnormalities. Arch Dermatol 1963; 88: 176-180.
55. Massone C, Parodi A, Rebora A. Erythema multiforme-like subacute cutaneous lupus erythematosus: A new variety? Acta Derm Venereol 2000; 80: 308-309.
56. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: A paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301: 65-70.
57. Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol 2001; 45: 315-316.
58. Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology 2007; 214: 85-88.